The EIC Accelerator programme can support
drug development projects

Elena Pérez holds an MSc in Analytical Chemistry (University of Oviedo, Spain, 2011) and a PhD in Bioscience Engineering (KU Leuven, Belgium, 2016). She has +10 years of R&D experience within top European Universities, including her PhD research in the framework of a Marie Skłodowska-Curie Innovative Training Network (2011-2015) and a collaborative technology transfer project with Abbott Laboratories (2016-2018). Since 2019, she combines her experience within R&D with her passion for innovation consulting and tech transfer working as an Innovation funding specialist. In this position, she helps companies to raise public funding for their innovative R&D projects and has been involved in +15 proposals at the national (CDTI PID, Neotec) and European levels (Horizon 2020, Eureka Network).

Want to know if your drug development project is eligible for funding?

The funding provided by the EIC Accelerator helps bridge the gap between advanced research and market launch. It provides grant money and equity investment (up to 17.5M€) to support high-risk innovative startups and SMEs to finish their product development and reach the market while supporting the scaling up of their business. Hence, it targets companies that are at a Technology Readiness Level (TRL) 6-8 and aims to help them reach TRL 9, namely ready for commercialization.

What are TRLs and can they be adapted to the pharmaceutical industry?

The Technology Readiness Level (TRL) scale is valuable a tool for assessing the maturity of technologies that intends to standardize the discussion of technical development across different industries. However, it may not be well suited for the pharmaceutical industry.

Drug development is a highly regulated process that involves expensive and extensive clinical trials before a product can be marketed. Therefore, the TRL scale used for engineering products and technologies, may not reflect the development status of startups in the Life Science industry.

TRL scale can be adapted to pharma startups

The EIC Accelerator program requirements for pharma startups reflect the unique challenges this industry faces to commercialize a product. Drug development projects must at least have completed the pre-clinical research studies and be in the Clinical Trial Phase I or II in order to be considered TRL 6-8 and eligible for funding. This means they have conducted the initial safety training and are starting to test the efficacy on a larger patient population. The funding provided by the EIC, along with a private pharmaceutical co-investment, can help complete the clinical trials and bring the product closer to a commercial stage or to a licensing agreement.

If you are working on a drug development project and meet the eligibility requirements for the EIC Accelerator programme, this could be the funding opportunity you have been looking for to bring your product to market.

At Euro-Funding we offer support throughout the entire grant identification, processing and justification process. If you have a project and you are looking for grants or subsidies to finance it, contact us and maximize the return of each project.

Consult the viability of your projects

LATEST BLOG NEWS

News

EU allocates € 6,6 Bn budget to fund transport infrastructures of the future

In a significant move towards advancing sustainable transportation and infrastructure development, the European Commission has announced the opening of a new call for projects under the Connecting Europe Facility (CEF) Transport. This latest call, launched on 26 September, is set to bolster cross-border transport connectivity and support the European Union’s vision for a greener and more integrated transport system. The call is now inviting project proposals, with the submission period scheduled to close on 30 January 2024.

David García Arrate 27 September, 2023

News

How will the return of UK in R&D programmes benefit the EU?

How will the return of UK in R&D programmes benefit the EU? Marie Latour x Settings THE RETURN OF THE UK TO HORIZON EUROPE Good

Marie Latour 27 September, 2023

News

Environmental projects that enhance sustainability.

Environmentally beneficial projects promoting sustainability through an overview of European funding opportunities for research, development, and innovation (R&D&I). It underscores the significance of tackling environmental challenges and spotlights key programs like Horizon Europe, LIFE, the Innovation Fund, and EUROSTARS. International collaboration and capitalizing on funding prospects are crucial in this context.

Óscar Salazar 29 August, 2023